Post-traumatic Stress Disorder Treatment Market Size, Trends, Share, Growth | Report 2022-2030
The global post-traumatic stress disorder treatment market size was estimated at around USD 915.8 million in 2021 and it is projected to hit around USD 1.57 billion by 2030, growing at a CAGR of 6.17% from 2022 to 2030.
Report Highlights
The increasing disease burden of post-traumatic stress disorder (PTSD), innovation in R&D and emerging drug pipeline, and efforts by government and non-profit organizations to increase awareness are the key factors augmenting the space growth.
The emerging drug pipeline, thereby, expected advancement and drug launches for the treatment of PTSD, is anticipated to offer a lucrative opportunity for market growth over the forecast period. This can be attributed to the presence of Aptinyx’s NYX-783, Bionomics’ BNC210, and Jazz Pharmaceuticals’ JZP150 under phase 2 clinical trials. Ahead of these, Otsuka Pharmaceutical’s Brexpiprazole and Zoloft Combination are in phase 3 trial, creating fierce competition among key players to launch the product in the space.
Events such as the COVID-19 pandemic further support space growth. Several studies have been conducted to understand the impact of the covid 19 pandemic on mental health, increasing the risk of PTSD and rising demand for its treatment. For instance, the August 2021 review article, "COVID?19 and Post traumatic Stress Disorder: The Perfect 'Storm' for Mental Health," clearly demonstrates an increase in the risk of development of PTSD among pandemic affected families and survivors.
Companies are strategically taking initiatives that aid in developing new products, regulatory approvals, and enhancing their product portfolio with geographical expansion. For instance, in March 2022, H. Lundbeck A/S granted the license agreement to Sun Pharmaceutical Industries Ltd., for marketing and distribute of Vortioxetine under the brand name Vortidiftm in the Indian market.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 915.8 million |
| Revenue Forecast by 2030 | USD 1.57 billion |
| Growth rate from 2022 to 2030 | CAGR of 6.17% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Drug Class, demographics, distribution channel, region |
| Companies Covered |
Lupin Limited; Pfizer, Inc.; Aurobindo Pharma Limited; Merck KGaA; GlaxoSmithKline plc.; Otsuka Pharmaceutical Development; Jazz Pharmaceuticals; Bionomics; Aptinyx; AstraZeneca |
Drug Class Insights
The antidepressants drug class segment dominated the PTSD treatment market in 2021. This can be attributed due to the presence of FDA approved SSRIs (selective serotonin reuptake inhibitors) such as Zoloft (sertraline) and Paxil (paroxetine) driving the space. They are recommended as first line of treatment for PTSD. The space also has a high presence of some off-label antidepressant drugs such as Serzone (nefazodone), Nardil (phenelzine), and Tofranil (imipramine) to treat the condition. However, these medications aren’t recommended for initial PTSD treatment.
Furthermore, key players are strategically undertaking initiatives such as collaborations, expansion, and partnerships to develop drugs and grow in the space. For example, in March 2022, H. Lundbeck A/S entered into licensing agreement for the antidepressant drug Vortioxetine to Sun Pharmaceutical Industries Ltd. Under this agreement, Sun Pharmaceutical Industries Ltd. will sell and distribute Vortioxetine under the brand name Vortidiftm in the Indian market. The key players are also developing and investigating combination therapies, including antidepressant drugs, for managing the condition. For example, Otsuka Pharmaceutical’s Brexpiprazole and Zoloft Combination is under phase 3 studies and expected launch of such combinations is anticipated to fuel the space.
Demographics Insights
The adult segment dominated the market and held 84.53% market share in 2021, owing to major chunk of patients in age group, rising disorder cases in the adult group, and increasing traumatic experiences. The group experience severe, moderate to mild impairment levels of symptoms. According to the research study, in the U.S., in 2021, serious impairment was reported for about 36% of patients, moderate impairment for about 33%, and mild for around 30% of patients. Moreover, childhood trauma also contributes to developing PTSD in adulthood. Furthermore, as reported, adult women have high prevalence of about 5.2% than adult men at about 1.8% for PTSD. Thus, owing to such factors segment is also expected to maintain its dominance over the forecast period.
Pharmacotherapy is prescribed to children who show persistent PTSD symptoms despite undergoing cognitive behavior therapy. There are currently no FDA approved Selective serotonin reuptake inhibitors (SSRIs) for the treatment of PTSD in children. However, growing awareness, increasing understanding of importance of mental health, are contributing to growth of the children demographic segment.
Distribution Channel Insights
The retail pharmacy segment dominated the market and accounted for the largest revenue share of 64.02% over the forecast period. As post-traumatic stress disorder treatment, control and management take short term as well as long term support of medications which offers retail pharmacies’ growth. In addition, retail pharmacies are at ease for most medications, especially in the homecare setting. All these factors are expected to fuel the market in coming years.
The others segment is expected to witness a CAGR of 3.0% during the forecast period. Presence of online pharmacy platform encourages the comfort of buying. The trend of online purchasing has upsurge due to the ease and home delivery flexibility, generating revenues, thereby driving the segment. Amid pandemic people also experienced the comfort of delivery services and reduce time and travel for prescription refill in retail stores.
Regional Insights
North America dominated the PTSD treatment market and accounted for the largest revenue share of 57.83% in 2021. The major factors driving the space include the rising prevalence of the PTSD and increasing patient awareness about mental health. For instance, according to PTSD statistics and facts, the prevalence of the condition in the U.S. was reported to about 3.6% in adults over 18 years of age. Increased in healthcare expenditure and presence of major players in the region is boosting the growth. Advance therapeutic options with expected new approvals and launches over the forecast period, and proactive government measures further contribute to regional growth.
Asia Pacific is estimated to witness the fastest growth rate in the coming years. The high growth rate can be attributed to rising burden of disorder and the increasing approach of patients to doctors for mental health. Positive changes, such as healthcare benefits by the government, increased awareness among the population, and increased willingness to avail medical treatment are also expected to drive the market in the region.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Post-traumatic Stress Disorder Treatment Market
5.1. COVID-19 Landscape: Post-traumatic Stress Disorder Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Post-traumatic Stress Disorder Treatment Market, By Drug Class
8.1. Post-traumatic Stress Disorder Treatment Market, by Drug Class, 2022-2030
8.1.1 Antidepressants
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Antipsychotics
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Anti-anxiety
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Post-traumatic Stress Disorder Treatment Market, By Demographics
9.1. Post-traumatic Stress Disorder Treatment Market, by Demographics, 2022-2030
9.1.1. Adult
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Children
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Post-traumatic Stress Disorder Treatment Market, By Distribution Channel
10.1. Post-traumatic Stress Disorder Treatment Market, by Distribution Channel, 2022-2030
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Post-traumatic Stress Disorder Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.1.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.5.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Demographics (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 12. Company Profiles
12.1. Lupin Limited
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Aurobindo Pharma Limited
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck KGaA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. GlaxoSmithKline plc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Otsuka Pharmaceutical Development
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Jazz Pharmaceuticals
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bionomics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Aptinyx
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. AstraZeneca
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers